Loading…
Neoadjuvant radiotherapy for resectable retroperitoneal sarcoma: a meta-analysis
Neoadjuvant radiotherapy (NRT) for resectable retroperitoneal sarcoma (RPS) has been shown to be systematically feasible. Whether NRT has equivalent or better clinical effects compared to surgery alone for RPS patients remains controversial. We performed a systematic literature search of PubMed, Web...
Saved in:
| Published in: | Radiation oncology (London, England) England), 2022-12, Vol.17 (1), p.215-11, Article 215 |
|---|---|
| Main Authors: | , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c535t-8e7324fcc57383f5e59db13c46a3170531d11eaaf9df188d4d3a8ce7d8a952fc3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c535t-8e7324fcc57383f5e59db13c46a3170531d11eaaf9df188d4d3a8ce7d8a952fc3 |
| container_end_page | 11 |
| container_issue | 1 |
| container_start_page | 215 |
| container_title | Radiation oncology (London, England) |
| container_volume | 17 |
| creator | Li, Xiangji Dong, Ruihan Xiao, Mengmeng Min, Li Luo, Chenghua |
| description | Neoadjuvant radiotherapy (NRT) for resectable retroperitoneal sarcoma (RPS) has been shown to be systematically feasible. Whether NRT has equivalent or better clinical effects compared to surgery alone for RPS patients remains controversial.
We performed a systematic literature search of PubMed, Web of Science, Embase, ASCO Abstracts, and Cochrane library databases for studies in humans with defined search terms. Articles were independently assessed by 2 reviewers, and only randomized controlled trials and cohort studies were included. The hazard ratios (HRs) of overall survival (OS), recurrence-free survival (RFS), and local recurrence (LR) were extracted from included studies. Heterogeneity among study-specific HRs was assessed by the Q statistic and I
statistic. Overall HR was assessed by random-effects or fixed-effects models. Publication bias was tested by Begg's tests, and the quality of each study was assessed with the Newcastle Ottawa Scale.
A total of 12 eligible studies with 7778 resectable RPS patients were finally included in this study. The pooled analysis revealed the distinct advantages of NRT as compared to surgery alone, including longer OS (HR = 0.81, P |
| doi_str_mv | 10.1186/s13014-022-02159-3 |
| format | article |
| fullrecord | <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_098de087ced543178764123b9b4c539a</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A731555751</galeid><doaj_id>oai_doaj_org_article_098de087ced543178764123b9b4c539a</doaj_id><sourcerecordid>A731555751</sourcerecordid><originalsourceid>FETCH-LOGICAL-c535t-8e7324fcc57383f5e59db13c46a3170531d11eaaf9df188d4d3a8ce7d8a952fc3</originalsourceid><addsrcrecordid>eNptkl9rFDEUxQdRbK1-AR9kwBdfpiaTZJL4IJTin0JRHxR8C3eTm22WmcmaZAv77c12aumChJDLzT0_TshpmteUnFOqhveZMkJ5R_q-bip0x540p1Ry1Ukqfz99VJ80L3LeEMIFI_p5c8IGIRVR_Wnz4xtGcJvdLcylTeBCLDeYYLtvfUxtwoy2wGrEWpYUt5hCiTPC2GZINk7woYV2wgIdzDDuc8gvm2cexoyv7s-z5tfnTz8vv3bX379cXV5cd1YwUTqFkvXcWyskU8wLFNqtKLN8AEYlEYw6ShHAa-epUo47BsqidAq06L1lZ83VwnURNmabwgRpbyIEc9eIaW0glWBHNEQrh0RJi07wSldy4LRnK73i1YyGyvq4sLa71YTO4lwSjEfQ45s53Jh1vDVa6uqfVsC7e0CKf3aYi5lCtjiOMGPcZdNLofuBScXr6NtldA3VWph9rER7GDcXFSWEkOIAPP_PVF0Op2DrD_hQ-0eCfhHYFHNO6B_cU2IOaTFLWkxNi7lLi2FV9Obxux8k_-LB_gJ8-7si</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2759263784</pqid></control><display><type>article</type><title>Neoadjuvant radiotherapy for resectable retroperitoneal sarcoma: a meta-analysis</title><source>PubMed Central database</source><source>ProQuest Publicly Available Content database</source><creator>Li, Xiangji ; Dong, Ruihan ; Xiao, Mengmeng ; Min, Li ; Luo, Chenghua</creator><creatorcontrib>Li, Xiangji ; Dong, Ruihan ; Xiao, Mengmeng ; Min, Li ; Luo, Chenghua</creatorcontrib><description>Neoadjuvant radiotherapy (NRT) for resectable retroperitoneal sarcoma (RPS) has been shown to be systematically feasible. Whether NRT has equivalent or better clinical effects compared to surgery alone for RPS patients remains controversial.
We performed a systematic literature search of PubMed, Web of Science, Embase, ASCO Abstracts, and Cochrane library databases for studies in humans with defined search terms. Articles were independently assessed by 2 reviewers, and only randomized controlled trials and cohort studies were included. The hazard ratios (HRs) of overall survival (OS), recurrence-free survival (RFS), and local recurrence (LR) were extracted from included studies. Heterogeneity among study-specific HRs was assessed by the Q statistic and I
statistic. Overall HR was assessed by random-effects or fixed-effects models. Publication bias was tested by Begg's tests, and the quality of each study was assessed with the Newcastle Ottawa Scale.
A total of 12 eligible studies with 7778 resectable RPS patients were finally included in this study. The pooled analysis revealed the distinct advantages of NRT as compared to surgery alone, including longer OS (HR = 0.81, P < 0.001), longer RFS (HR = 0.58, P = 0.04), and lower LR (HR = 0.70, P = 0.03). No evidence of publication bias was observed.
NRT is likely to be beneficial for resectable RPS patients in terms of OS and RFS. However, more multicenter clinical trials are needed to confirm these findings.</description><identifier>ISSN: 1748-717X</identifier><identifier>EISSN: 1748-717X</identifier><identifier>DOI: 10.1186/s13014-022-02159-3</identifier><identifier>PMID: 36578082</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Care and treatment ; Diagnosis ; Humans ; Meta-analysis ; Methods ; Multicenter Studies as Topic ; Neoadjuvant radiotherapy ; Neoadjuvant Therapy ; Patient outcomes ; Retroperitoneal Neoplasms - radiotherapy ; Retroperitoneal Neoplasms - surgery ; Retroperitoneal sarcoma ; Sarcoma ; Sarcoma - radiotherapy ; Sarcoma - surgery ; Soft Tissue Neoplasms ; Soft tissue sarcoma</subject><ispartof>Radiation oncology (London, England), 2022-12, Vol.17 (1), p.215-11, Article 215</ispartof><rights>2022. The Author(s).</rights><rights>COPYRIGHT 2022 BioMed Central Ltd.</rights><rights>The Author(s) 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c535t-8e7324fcc57383f5e59db13c46a3170531d11eaaf9df188d4d3a8ce7d8a952fc3</citedby><cites>FETCH-LOGICAL-c535t-8e7324fcc57383f5e59db13c46a3170531d11eaaf9df188d4d3a8ce7d8a952fc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9795731/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9795731/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,37013,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36578082$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Li, Xiangji</creatorcontrib><creatorcontrib>Dong, Ruihan</creatorcontrib><creatorcontrib>Xiao, Mengmeng</creatorcontrib><creatorcontrib>Min, Li</creatorcontrib><creatorcontrib>Luo, Chenghua</creatorcontrib><title>Neoadjuvant radiotherapy for resectable retroperitoneal sarcoma: a meta-analysis</title><title>Radiation oncology (London, England)</title><addtitle>Radiat Oncol</addtitle><description>Neoadjuvant radiotherapy (NRT) for resectable retroperitoneal sarcoma (RPS) has been shown to be systematically feasible. Whether NRT has equivalent or better clinical effects compared to surgery alone for RPS patients remains controversial.
We performed a systematic literature search of PubMed, Web of Science, Embase, ASCO Abstracts, and Cochrane library databases for studies in humans with defined search terms. Articles were independently assessed by 2 reviewers, and only randomized controlled trials and cohort studies were included. The hazard ratios (HRs) of overall survival (OS), recurrence-free survival (RFS), and local recurrence (LR) were extracted from included studies. Heterogeneity among study-specific HRs was assessed by the Q statistic and I
statistic. Overall HR was assessed by random-effects or fixed-effects models. Publication bias was tested by Begg's tests, and the quality of each study was assessed with the Newcastle Ottawa Scale.
A total of 12 eligible studies with 7778 resectable RPS patients were finally included in this study. The pooled analysis revealed the distinct advantages of NRT as compared to surgery alone, including longer OS (HR = 0.81, P < 0.001), longer RFS (HR = 0.58, P = 0.04), and lower LR (HR = 0.70, P = 0.03). No evidence of publication bias was observed.
NRT is likely to be beneficial for resectable RPS patients in terms of OS and RFS. However, more multicenter clinical trials are needed to confirm these findings.</description><subject>Care and treatment</subject><subject>Diagnosis</subject><subject>Humans</subject><subject>Meta-analysis</subject><subject>Methods</subject><subject>Multicenter Studies as Topic</subject><subject>Neoadjuvant radiotherapy</subject><subject>Neoadjuvant Therapy</subject><subject>Patient outcomes</subject><subject>Retroperitoneal Neoplasms - radiotherapy</subject><subject>Retroperitoneal Neoplasms - surgery</subject><subject>Retroperitoneal sarcoma</subject><subject>Sarcoma</subject><subject>Sarcoma - radiotherapy</subject><subject>Sarcoma - surgery</subject><subject>Soft Tissue Neoplasms</subject><subject>Soft tissue sarcoma</subject><issn>1748-717X</issn><issn>1748-717X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNptkl9rFDEUxQdRbK1-AR9kwBdfpiaTZJL4IJTin0JRHxR8C3eTm22WmcmaZAv77c12aumChJDLzT0_TshpmteUnFOqhveZMkJ5R_q-bip0x540p1Ry1Ukqfz99VJ80L3LeEMIFI_p5c8IGIRVR_Wnz4xtGcJvdLcylTeBCLDeYYLtvfUxtwoy2wGrEWpYUt5hCiTPC2GZINk7woYV2wgIdzDDuc8gvm2cexoyv7s-z5tfnTz8vv3bX379cXV5cd1YwUTqFkvXcWyskU8wLFNqtKLN8AEYlEYw6ShHAa-epUo47BsqidAq06L1lZ83VwnURNmabwgRpbyIEc9eIaW0glWBHNEQrh0RJi07wSldy4LRnK73i1YyGyvq4sLa71YTO4lwSjEfQ45s53Jh1vDVa6uqfVsC7e0CKf3aYi5lCtjiOMGPcZdNLofuBScXr6NtldA3VWph9rER7GDcXFSWEkOIAPP_PVF0Op2DrD_hQ-0eCfhHYFHNO6B_cU2IOaTFLWkxNi7lLi2FV9Obxux8k_-LB_gJ8-7si</recordid><startdate>20221228</startdate><enddate>20221228</enddate><creator>Li, Xiangji</creator><creator>Dong, Ruihan</creator><creator>Xiao, Mengmeng</creator><creator>Min, Li</creator><creator>Luo, Chenghua</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><general>BMC</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20221228</creationdate><title>Neoadjuvant radiotherapy for resectable retroperitoneal sarcoma: a meta-analysis</title><author>Li, Xiangji ; Dong, Ruihan ; Xiao, Mengmeng ; Min, Li ; Luo, Chenghua</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c535t-8e7324fcc57383f5e59db13c46a3170531d11eaaf9df188d4d3a8ce7d8a952fc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Care and treatment</topic><topic>Diagnosis</topic><topic>Humans</topic><topic>Meta-analysis</topic><topic>Methods</topic><topic>Multicenter Studies as Topic</topic><topic>Neoadjuvant radiotherapy</topic><topic>Neoadjuvant Therapy</topic><topic>Patient outcomes</topic><topic>Retroperitoneal Neoplasms - radiotherapy</topic><topic>Retroperitoneal Neoplasms - surgery</topic><topic>Retroperitoneal sarcoma</topic><topic>Sarcoma</topic><topic>Sarcoma - radiotherapy</topic><topic>Sarcoma - surgery</topic><topic>Soft Tissue Neoplasms</topic><topic>Soft tissue sarcoma</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Li, Xiangji</creatorcontrib><creatorcontrib>Dong, Ruihan</creatorcontrib><creatorcontrib>Xiao, Mengmeng</creatorcontrib><creatorcontrib>Min, Li</creatorcontrib><creatorcontrib>Luo, Chenghua</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals at publisher websites</collection><jtitle>Radiation oncology (London, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Li, Xiangji</au><au>Dong, Ruihan</au><au>Xiao, Mengmeng</au><au>Min, Li</au><au>Luo, Chenghua</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Neoadjuvant radiotherapy for resectable retroperitoneal sarcoma: a meta-analysis</atitle><jtitle>Radiation oncology (London, England)</jtitle><addtitle>Radiat Oncol</addtitle><date>2022-12-28</date><risdate>2022</risdate><volume>17</volume><issue>1</issue><spage>215</spage><epage>11</epage><pages>215-11</pages><artnum>215</artnum><issn>1748-717X</issn><eissn>1748-717X</eissn><abstract>Neoadjuvant radiotherapy (NRT) for resectable retroperitoneal sarcoma (RPS) has been shown to be systematically feasible. Whether NRT has equivalent or better clinical effects compared to surgery alone for RPS patients remains controversial.
We performed a systematic literature search of PubMed, Web of Science, Embase, ASCO Abstracts, and Cochrane library databases for studies in humans with defined search terms. Articles were independently assessed by 2 reviewers, and only randomized controlled trials and cohort studies were included. The hazard ratios (HRs) of overall survival (OS), recurrence-free survival (RFS), and local recurrence (LR) were extracted from included studies. Heterogeneity among study-specific HRs was assessed by the Q statistic and I
statistic. Overall HR was assessed by random-effects or fixed-effects models. Publication bias was tested by Begg's tests, and the quality of each study was assessed with the Newcastle Ottawa Scale.
A total of 12 eligible studies with 7778 resectable RPS patients were finally included in this study. The pooled analysis revealed the distinct advantages of NRT as compared to surgery alone, including longer OS (HR = 0.81, P < 0.001), longer RFS (HR = 0.58, P = 0.04), and lower LR (HR = 0.70, P = 0.03). No evidence of publication bias was observed.
NRT is likely to be beneficial for resectable RPS patients in terms of OS and RFS. However, more multicenter clinical trials are needed to confirm these findings.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>36578082</pmid><doi>10.1186/s13014-022-02159-3</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1748-717X |
| ispartof | Radiation oncology (London, England), 2022-12, Vol.17 (1), p.215-11, Article 215 |
| issn | 1748-717X 1748-717X |
| language | eng |
| recordid | cdi_doaj_primary_oai_doaj_org_article_098de087ced543178764123b9b4c539a |
| source | PubMed Central database; ProQuest Publicly Available Content database |
| subjects | Care and treatment Diagnosis Humans Meta-analysis Methods Multicenter Studies as Topic Neoadjuvant radiotherapy Neoadjuvant Therapy Patient outcomes Retroperitoneal Neoplasms - radiotherapy Retroperitoneal Neoplasms - surgery Retroperitoneal sarcoma Sarcoma Sarcoma - radiotherapy Sarcoma - surgery Soft Tissue Neoplasms Soft tissue sarcoma |
| title | Neoadjuvant radiotherapy for resectable retroperitoneal sarcoma: a meta-analysis |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T10%3A27%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Neoadjuvant%20radiotherapy%20for%20resectable%20retroperitoneal%20sarcoma:%20a%20meta-analysis&rft.jtitle=Radiation%20oncology%20(London,%20England)&rft.au=Li,%20Xiangji&rft.date=2022-12-28&rft.volume=17&rft.issue=1&rft.spage=215&rft.epage=11&rft.pages=215-11&rft.artnum=215&rft.issn=1748-717X&rft.eissn=1748-717X&rft_id=info:doi/10.1186/s13014-022-02159-3&rft_dat=%3Cgale_doaj_%3EA731555751%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c535t-8e7324fcc57383f5e59db13c46a3170531d11eaaf9df188d4d3a8ce7d8a952fc3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2759263784&rft_id=info:pmid/36578082&rft_galeid=A731555751&rfr_iscdi=true |